
Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML.

Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML.

In a recent study, people who lived in disadvantaged or rural areas were just as likely to receive the second-generation medications as people in urban areas.

However, a survival benefit was observed with using a signaling inhibitor in general for patients with angioimmunoblastic T-cell lymphoma.

The authors note that CAR-T cell therapy could change the treatment standard for patients with DLBCL, who previously had few options if standard chemotherapy treatment was ineffective.

Encourage patients to locate and safely store their immunization records

The cases focus on acne, atopic dermatitis and steroids, warts and wart remover, and athlete’s foot.

Investigators found that individuals who self-identified as Black were less frequently imaged for cognitive impairment with MRI and at an older age compared with White and Hispanic patients.

An overview of how gene therapy has evolved since its inception, current applications, and emerging challenges.

The model may help clinicians identify patients who would benefit from disease-specific therapies or enrollment into clinical trials.

The study results demonstrated that 92% of patients treated with benralizumab were able to safely reduce inhaled steroid dose, and more than 60% could stop use entirely.

The results found that 93% of individuals in the high-risk group presented persistently positive antiphospholipid antibodies, compared with 47% of individuals in the lower-risk group.

Encouraging patients to take a proactive approach to their heart health can have great benefits

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.


The study authors note that the Best ACT-S questionnaire complements the Best ACT-P questionnaire, a previously developed questionnaire that assesses preschool-aged patients with asthma.

Expert breaks down these findings and more from the GLAMM1 study at the 2023 ASH Annual Meeting.

Only 20% of the patient population were reported as being “very good” sleepers when it comes to sleep disturbances.

Seven new agents have received FDA approval since October 2022.

By combining the administration of psychedelic compounds with therapeutic support, ketamine-assisted therapy is proving remarkable efficacy in treating mental health conditions.

More drugs plus a growing population of older and sicker patients is creating medication-alert overload for already stressed clinicians.

The bacteria were shown to contain a membrane-bound organelle structure that is like those found in eukaryotic cells.

This is the first trial to show that a measurable residual disease (MRD)–guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of progression-free survival and overall survival.

The study results shine a light on the potential need for further policy changes that promote gender equity and bridge the gap in R01 funding awarded to female applicants.

Almost 80% of patients have now stopped treatment with ribociclib, but benefit persists and is greater than it was 6 months ago, according to the presenter.

Median overall survival is set to be more than 2 years, which is more than double the overall survival of current frontline therapies.

He also provides insight for students training in classical hematology, oncology hematology, or oncology pharmacy.

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

The study findings have implications for the identification of novel pathways with which to selectively target folate-metabolism blood cancers.

The president highlights a new curative treatment option for sickle cell disease while also expanding on the changing treatment landscape for hematologic conditions.

The approval marks isavuconazonium sulfate as the only granted azole antifungal therapy for pediatric patients with invasive aspergillosia and invasive mucormycotic who are as young as age 1.